Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy

V. Ferencz, S. Meszaros, E. Csupor, E. Toth, K. Bors, A. Falus, C. Horváth

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: Our aim was to investigate whether pollen-allergy can affect bone mass and fractures in postmenopausal women. Methods: A total of 125 postmenopausal pollen-allergic women (mean age: 61.26 yr) were split into four groups: (1) treated with neither H1 histamine receptor (H1R) antagonist nor inhaled corticosteroid (n=43); (2) treated only with H1R antagonist (n=53); (3) treated with both H1R antagonist and inhaled corticosteroid (n=17); (4) treated with only inhaled corticosteroid (n=12). Treatment, in the appropriate groups, had occurred for at least 5 years, seasonally. One-hundred non-allergic postmenopausal subjects matched for age, body mass index (BMI), and age at menopause served as controls. Results: Overweight and obesity (25 kg/m 2≤BMI) were common among the allergic women (76%). Allergic patients without treatment had a slightly lower bone density than their non-allergic counterparts. The rate (34.9%) of prevalent low-energy fractures (distal forearm, hip, and clinical vertebral fractures) in untreated allergic patients was almost triple that observed in non-allergic women (13%, chi 2 p=0.003). Bone fracture occurred more often in H1R-only treated patients (30.19%) than in controls (chi2 p=0.01); however, clinical vertebral or hip fractures developed neither in those treated only with H1R antagonist nor in those who received both H1R antagonist and inhaled corticosteroid. Bone fractures were more frequent among patients with inhaled steroid treatment than among patients with a combined treatment of inhaled steroid and antihistamine (50 versus 29.4%). BMI predicted prevalent fractures at 1.278 (95% CI: 1.047-1.559, p=0.016) for a 1 kg/m2 increase among untreated allergic patients. Conclusion: In conclusion, we found a high prevalence of low-energy fractures among pollen-allergic postmenopausal women which was associated with obesity. It is possible that the H1R antagonists compensate for both the negative effect of pollen-allergy and the adverse effect of inhaled corticosteroid treatment on bone fracture risk.

Original languageEnglish
Pages (from-to)484-491
Number of pages8
JournalOsteoporosis International
Volume17
Issue number3
DOIs
Publication statusPublished - Mar 2006

Fingerprint

Histamine H1 Antagonists
Seasonal Allergic Rhinitis
Bone Fractures
Adrenal Cortex Hormones
Pollen
Body Mass Index
Obesity
Steroids
Therapeutics
Histamine H1 Receptors
Histamine Antagonists
Hip Fractures
Menopause
Forearm
Bone Density
Hip

Keywords

  • Bone mineral density
  • Fractures
  • H1 histamine receptor antagonist
  • Obesity
  • Pollen-allergy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy. / Ferencz, V.; Meszaros, S.; Csupor, E.; Toth, E.; Bors, K.; Falus, A.; Horváth, C.

In: Osteoporosis International, Vol. 17, No. 3, 03.2006, p. 484-491.

Research output: Contribution to journalArticle

Ferencz, V. ; Meszaros, S. ; Csupor, E. ; Toth, E. ; Bors, K. ; Falus, A. ; Horváth, C. / Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy. In: Osteoporosis International. 2006 ; Vol. 17, No. 3. pp. 484-491.
@article{d653ab655dd5475abec10e248dedc545,
title = "Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy",
abstract = "Introduction: Our aim was to investigate whether pollen-allergy can affect bone mass and fractures in postmenopausal women. Methods: A total of 125 postmenopausal pollen-allergic women (mean age: 61.26 yr) were split into four groups: (1) treated with neither H1 histamine receptor (H1R) antagonist nor inhaled corticosteroid (n=43); (2) treated only with H1R antagonist (n=53); (3) treated with both H1R antagonist and inhaled corticosteroid (n=17); (4) treated with only inhaled corticosteroid (n=12). Treatment, in the appropriate groups, had occurred for at least 5 years, seasonally. One-hundred non-allergic postmenopausal subjects matched for age, body mass index (BMI), and age at menopause served as controls. Results: Overweight and obesity (25 kg/m 2≤BMI) were common among the allergic women (76{\%}). Allergic patients without treatment had a slightly lower bone density than their non-allergic counterparts. The rate (34.9{\%}) of prevalent low-energy fractures (distal forearm, hip, and clinical vertebral fractures) in untreated allergic patients was almost triple that observed in non-allergic women (13{\%}, chi 2 p=0.003). Bone fracture occurred more often in H1R-only treated patients (30.19{\%}) than in controls (chi2 p=0.01); however, clinical vertebral or hip fractures developed neither in those treated only with H1R antagonist nor in those who received both H1R antagonist and inhaled corticosteroid. Bone fractures were more frequent among patients with inhaled steroid treatment than among patients with a combined treatment of inhaled steroid and antihistamine (50 versus 29.4{\%}). BMI predicted prevalent fractures at 1.278 (95{\%} CI: 1.047-1.559, p=0.016) for a 1 kg/m2 increase among untreated allergic patients. Conclusion: In conclusion, we found a high prevalence of low-energy fractures among pollen-allergic postmenopausal women which was associated with obesity. It is possible that the H1R antagonists compensate for both the negative effect of pollen-allergy and the adverse effect of inhaled corticosteroid treatment on bone fracture risk.",
keywords = "Bone mineral density, Fractures, H1 histamine receptor antagonist, Obesity, Pollen-allergy",
author = "V. Ferencz and S. Meszaros and E. Csupor and E. Toth and K. Bors and A. Falus and C. Horv{\'a}th",
year = "2006",
month = "3",
doi = "10.1007/s00198-005-0011-z",
language = "English",
volume = "17",
pages = "484--491",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "3",

}

TY - JOUR

T1 - Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy

AU - Ferencz, V.

AU - Meszaros, S.

AU - Csupor, E.

AU - Toth, E.

AU - Bors, K.

AU - Falus, A.

AU - Horváth, C.

PY - 2006/3

Y1 - 2006/3

N2 - Introduction: Our aim was to investigate whether pollen-allergy can affect bone mass and fractures in postmenopausal women. Methods: A total of 125 postmenopausal pollen-allergic women (mean age: 61.26 yr) were split into four groups: (1) treated with neither H1 histamine receptor (H1R) antagonist nor inhaled corticosteroid (n=43); (2) treated only with H1R antagonist (n=53); (3) treated with both H1R antagonist and inhaled corticosteroid (n=17); (4) treated with only inhaled corticosteroid (n=12). Treatment, in the appropriate groups, had occurred for at least 5 years, seasonally. One-hundred non-allergic postmenopausal subjects matched for age, body mass index (BMI), and age at menopause served as controls. Results: Overweight and obesity (25 kg/m 2≤BMI) were common among the allergic women (76%). Allergic patients without treatment had a slightly lower bone density than their non-allergic counterparts. The rate (34.9%) of prevalent low-energy fractures (distal forearm, hip, and clinical vertebral fractures) in untreated allergic patients was almost triple that observed in non-allergic women (13%, chi 2 p=0.003). Bone fracture occurred more often in H1R-only treated patients (30.19%) than in controls (chi2 p=0.01); however, clinical vertebral or hip fractures developed neither in those treated only with H1R antagonist nor in those who received both H1R antagonist and inhaled corticosteroid. Bone fractures were more frequent among patients with inhaled steroid treatment than among patients with a combined treatment of inhaled steroid and antihistamine (50 versus 29.4%). BMI predicted prevalent fractures at 1.278 (95% CI: 1.047-1.559, p=0.016) for a 1 kg/m2 increase among untreated allergic patients. Conclusion: In conclusion, we found a high prevalence of low-energy fractures among pollen-allergic postmenopausal women which was associated with obesity. It is possible that the H1R antagonists compensate for both the negative effect of pollen-allergy and the adverse effect of inhaled corticosteroid treatment on bone fracture risk.

AB - Introduction: Our aim was to investigate whether pollen-allergy can affect bone mass and fractures in postmenopausal women. Methods: A total of 125 postmenopausal pollen-allergic women (mean age: 61.26 yr) were split into four groups: (1) treated with neither H1 histamine receptor (H1R) antagonist nor inhaled corticosteroid (n=43); (2) treated only with H1R antagonist (n=53); (3) treated with both H1R antagonist and inhaled corticosteroid (n=17); (4) treated with only inhaled corticosteroid (n=12). Treatment, in the appropriate groups, had occurred for at least 5 years, seasonally. One-hundred non-allergic postmenopausal subjects matched for age, body mass index (BMI), and age at menopause served as controls. Results: Overweight and obesity (25 kg/m 2≤BMI) were common among the allergic women (76%). Allergic patients without treatment had a slightly lower bone density than their non-allergic counterparts. The rate (34.9%) of prevalent low-energy fractures (distal forearm, hip, and clinical vertebral fractures) in untreated allergic patients was almost triple that observed in non-allergic women (13%, chi 2 p=0.003). Bone fracture occurred more often in H1R-only treated patients (30.19%) than in controls (chi2 p=0.01); however, clinical vertebral or hip fractures developed neither in those treated only with H1R antagonist nor in those who received both H1R antagonist and inhaled corticosteroid. Bone fractures were more frequent among patients with inhaled steroid treatment than among patients with a combined treatment of inhaled steroid and antihistamine (50 versus 29.4%). BMI predicted prevalent fractures at 1.278 (95% CI: 1.047-1.559, p=0.016) for a 1 kg/m2 increase among untreated allergic patients. Conclusion: In conclusion, we found a high prevalence of low-energy fractures among pollen-allergic postmenopausal women which was associated with obesity. It is possible that the H1R antagonists compensate for both the negative effect of pollen-allergy and the adverse effect of inhaled corticosteroid treatment on bone fracture risk.

KW - Bone mineral density

KW - Fractures

KW - H1 histamine receptor antagonist

KW - Obesity

KW - Pollen-allergy

UR - http://www.scopus.com/inward/record.url?scp=33645230177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645230177&partnerID=8YFLogxK

U2 - 10.1007/s00198-005-0011-z

DO - 10.1007/s00198-005-0011-z

M3 - Article

VL - 17

SP - 484

EP - 491

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 3

ER -